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Abstract: Fullerenes have attracted considerable attention in different ﬁ  elds of science since 
their discovery in 1985. Investigations of physical, chemical and biological properties of 
fullerenes have yielded promising information. It is inferred that size, hydrophobicity, three-
dimensionality and electronic conﬁ  gurations make them an appealing subject in medicinal 
chemistry. Their unique carbon cage structure coupled with immense scope for derivatization 
make them a potential therapeutic agent. The study of biological applications has attracted 
increasing attention despite the low solubility of carbon spheres in physiological media.
The fullerene family, and especially C60, has appealing photo, electrochemical and physical 
properties, which can be exploited in various medical ﬁ  elds. Fullerene is able to ﬁ  t inside the 
hydrophobic cavity of HIV proteases, inhibiting the access of substrates to the catalytic site of 
enzyme. It can be used as radical scavenger and antioxidant. At the same time, if exposed to 
light, fullerene can produce singlet oxygen in high quantum yields. This action, together with 
direct electron transfer from excited state of fullerene and DNA bases, can be used to cleave 
DNA. In addition, fullerenes have been used as a carrier for gene and drug delivery systems. 
Also they are used for serum protein proﬁ  ling as MELDI material for biomarker discovery. 
In this review we report the aspects of medicinal applications of fullerenes.
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Introduction
An important area of research in modern material nanoscience concerns carbon-
based materials, among which fullerenes take one of the ﬁ  rst places. Since their ﬁ  rst 
detection and bulk production, they have gained a prime role on scientiﬁ  c scene, 
reaching the climax when 1996 Nobel Prize for Chemistry was awarded to Kroto, 
Curl and Smalley for their seminal discovery (Kroto et al 1985). [60]Fullerene, the 
most abundant representative of the fullerene family was produced for the ﬁ  rst time 
on a preparative scale in 1990, by resistive heating of graphite (Kraetschmer et al 
1990). Fullerene molecules are composed entirely of carbon, in form of a hollow 
sphere, ellipsoid or tube. Spherical fullerenes are also referred to as buckyballs. An 
important property of C60 molecule is its high symmetry. There are 120 symmetrical 
operations, like rotation around the axis and reﬂ  ection in a plane, which map the 
molecule onto itself. This makes C60 the most symmetrical molecule (Taylor et al 
1990). The C60 fullerene surface contains 20 hexagons and 12 pentagons. All the 
rings are fused; all the double bonds are conjugated. In spite of their extreme conjuga-
tion, they behave chemically and physically as electron-deﬁ  cient alkenes rather than 
electron rich aromatic systems (Fowler and Ceulemans 1995). The unique physical 
and chemical properties of these new forms of carbon led many scientists to predict 
several technological applications. However, the difﬁ  cult processibility of fullerenes 
has presented a major problem in hectic search for medicinal applications. C60 are 
insoluble in aqueous media and aggregate very easily (Prato 1997). There have been International Journal of Nanomedicine 2007:2(4) 640
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several attempts to overcome the natural repulsion of fuller-
enes for water. The most widely used methodologies are:
 (a)    Encapsulation or micro-encapsulation in special 
carriers like cyclodextrins (Youle and Karbowski 
2005), calixarenes (Shinkai and Ikeda 1998), 
polyvinylpyrrolidone (Yamakoshi et al 1994), 
micelles and liposomes (Bensasson et al 1994). In 
addition, the combination of fullerenes and lipid 
membranes has led to very interesting results. 
Lipid bilayers are dynamically mobile structures, 
partially ordered and of biopharmaceutical interest 
for covering biocompatible surfaces or for the 
controlled release of drugs (Hetzer et al 1997);
 (b)    Suspension with the help of co-solvents by saturating 
fullerenes in benzene solutions poured into THF. 
The resulting mixture is added dropwise to acetone, 
and then water is slowly added. A yellow suspen-
sion is formed and solvents are evaporated to a ﬁ  nal 
known volume of water (Scrivens et al 1994);
 (c)    Chemical functionalization to increase the 
hydrophilicity eg, with amino acid, carboxylic 
acid, polyhydroxyl group, amphiphilic polymers 
etc (Hirsch et al 1994; Bianco et al 1996; Brettreich 
and Hirsch 1998; Chen et al 2001).
The current list of fullerene derivatives covers practically 
all known classes of chemical compounds, demonstrating 
both high chemical activity and a broad versatility of 
chemical reactions. This outstanding chemical appearance 
generates great interest for their practical applications in 
creating novel materials for medical use. In this review we are 
reporting the medical applications of fullerenes, including, 
antiviral activity, antioxidant activity and their use in drug 
delivery. In addition, the powerful photoinduced biological 
activities as a potential scaffold for photodynamic therapy 
and diagnostic applications are highlighted.
Antiviral activity
Compounds with antiviral activity are generally of great 
medical interest and different modes of pharmaceutical 
actions have been described. Replication of the human 
immunodeﬁ  ciency virus (HIV) can be suppressed by several 
antiviral compounds, which are effective in preventing or 
delaying the onset of acquired immunodeﬁ  ciency syndrome 
(AIDS). Fullerenes (C60) and their derivatives have potential 
antiviral activity, which has strong implications on the 
treatment of HIV-infection. The antiviral activity of fullerene 
derivatives is based on several biological properties including 
their unique molecular architecture and antioxidant activity. 
It has been shown that fullerenes derivatives can inhibit and 
make complex with HIV protease (HIV-P) (Friedman et al 
1993; Sijbesma et al 1993). Dendrofullerene 1 (Figure 1) 
has shown the highest anti-protease activity (Brettreich 
and Hirsch 1998; Schuster et al 2000). Derivative 2, the 
trans-2 isomer (Figure 1), is a strong inhibitor of HIV-1 
replication. The study suggests that relative position (trans-2) 
of substituents on fullerenes and positive charges near to 
fullerenes cage provide an antiviral structural activity.
Fulleropyrrolidines with two ammonium groups have been 
found active against HIV-1 and HIV-2 (Marchesan et al 2005). 
The relative positions of side chains on fullerenes have a strong 
inﬂ  uence on antiviral activity. A series of fullerene derivatives 
have been synthesized to elucidate the structural parameters 
that affect antiviral activity of fullerenes. Figure 2 shows the 
derivatives, which are employed in lymphocyte CEM cell 
Figure 1 Structures of compounds 1 and 2. Copyright © 1998. Reproduced with permission from Brettreich M, Hirsch A. 1998. A highly water-soluble dendro[60]fullerene. 
Tetrahedron Lett, 39:2731–34.
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cultures infected with HIV-1 or HIV-2. The results reveal that 
trans fullerenes derivatives are more active than cis- counter-
parts whereas the equatorial one is totally inactive.
Fullerenes C60 derivatized with two or more solubilizing 
side chains have also been active, when tested in lymphocyte 
CEM cell cultures infected with HIV-1 and HIV-2 (Bosi 
et al 2003). Although derivatization of fullerenes with 
pyrrolidinium nitrogen enhances their solubility, the practical 
use of this method is limited by the generation of different 
isomers, whose separation is difﬁ  cult. Activity results prove 
that these derivatives are completely inactive against HIV-2, 
whereas the derivatives with corresponding quaternary salts 
at the pyrrolidine nitrogen are impinging against HIV-1. This 
ﬁ  nding is important to understand the electrostatic interactions 
and the structure of compounds with antiviral activity.
Amino acid derivatives of fullerene C60 (ADF) are 
found to inhibit HIV and human cytomegalovirus replication 
(Kotelnikova et al 2003). The selected fullerene derivatives are 
rendered water soluble by attachment of amino acids to C60: 
C60-l-Ala, C60-l-Ser, C60-l-Gly, C60-l-Arg and C60-d-Arg, 
C60-ACA (C60-ε-aminocaproic acid), C60-ACNa (sodium 
salt of C60-ACA), C60-ABA (C60-γ-aminobutyric acid) 
and C60-ABNa (sodium salt of C60-ABA) (Romanova et al 
1994). The mechanism is based on penetration of ADF car-
rying bivalent metal ions through lipid bilayer of liposomes, 
insertion to the hydrophobic domains of proteins and changing 
their functions of membrane bound enzymes. The observation 
that fullerenes and C60 derivatives are not immunogenetic fur-
ther supports their potential as pharmaceutical compounds.
On the other hand, water-insoluble fullerene (C60) deriva-
tives have antiviral activity against enveloped viruses. After 
visible light illumination for 5 h of semliki forest virus (SFV, 
Togaviridae) or vesicular stomatitis virus (VSV, Rhabdoviridae) 
(Kaesermann and Kempf 1997) in the presence of C60, the 
infectivity of these viruses is lost. This effect is attributed to the 
generation of singlet oxygen and is equally effective in solutions 
that contained proteins. Several dyes are available that allow sin-
glet oxygen generation (Rywkin et al 1995). Figure 3 shows the 
time-dependent loss of infectivity of SFV after illumination in 
the presence of C60 and oxygen. The light induced inactivation 
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Figure 2 Structures of Fulleropyrrolidines. Copyright © 2005. Reproduced with permission from Marchesan S, Da Ros T, Spalluto G, et al. 2005. Anti-HIV properties of 
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can be suppressed by removing oxygen from the solution by 
ﬂ  ushing argon through the suspension.
Cationic, anionic and amino acid type fullerene derivatives 
inhibit HIV-reverse transcriptase and hepatitis C virus 
replication (Mashino et al 2005). Anionic fullerene derivatives 
show antioxidant properties whereas cationic derivatives have 
the antibacterial and antiproliferative activities. The amino 
acid type derivatives are found to be the most active out of 
all the derivatives of fullerenes. All the fullerene derivatives 
tested are more active than the non-nucleoside analog of 
HIV-RT inhibitor. Derivatization of fullerenes with long 
alkyl chains had a negative effect on their antiviral activity. 
The two important targets for anti-HIV characteristics are the 
HIV-protease and HIV-reverse transcriptase. Studies based 
on molecular modeling data suggest that the C60-core can 
penetrate into the hydrophobic binding site of HIV protease. 
However, the hypothesis that HIV-protease inhibition is the 
main mechanism of the anti-viral activity of fullerene and its 
derivatives still lacks direct experimental proof.
The suggested mode of action of fullerene derivatives as 
anti-HIV compounds is further investigated by studies of the 
spatial hydrophobic relationship between C60 and the cavity 
regions of HIV-protease, which is a homodimeric enzyme that 
belongs to the class of aspartic proteases (Zhu et al 2003). 
The study is based on simulations of molecular dynamics, 
free energy techniques and simulations of the effect of C60 
on water content of the cavity. The hydrophobic interactions 
between C60 and cavity regions hold the inhibitor tightly and 
as a result cause the release of water, which provides indirect 
evidence for inhibitor presence. Some fullerene derivatives are 
found to have an inhibition constant of 53 μM and desolvation 
happens over 333–352 Å of active cavity. The free energy 
proﬁ  les prove a connection of opening and closing of ﬂ  aps 
in the cavity to the potential inhibitor binding.
The synthesis and characterization of fullerene derivatives 
as inhibitors of HIV aspartic protease enzyme holds great 
potential for the development of novel anti HIV drug 
(Marcorin et al 2000). The active region of HIV protease is 
a cylindrical hydrophobic cavity (diameter ~10 Å), which 
contains two amino acid residues, aspartate 25 and aspartate 
125, whose binding causes suppression of protein slicing and 
inhibits viral replication. The study is carried out with a water-
soluble fullerene derivative on peripheral blood mononuclear 
cells (PBMC). The mode of action is based on electrostatic 
and/or hydrogen bond interactions of fullerenes derivative 
side chains with Asp 25 and Asp 125, as shown in Figure 4.
Fullerenes as photosensitizers
Another potential medical application of C60 is related to 
the photoexcitation of fullerenes. In fact, fullerene can be 
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Figure 3 Kinetics of the photodynamic inactivation of SFV by C60. SFV was illuminated with visible light in the presence of C60 under constant stirring and O2 bubbling (•). 
Mean values and standard errors from three independent experiments are shown. Controls include the incubation of SFV with C60 without illumination (∇), the illumination 
of SFV without C60 (o) and the illumination with C60 under constant stirring and ﬂ  ushing with argon (@). Copyright © 1995. Reproduced with permission from Rywkin S, 
Ben-Hur E, Reid ME, et al. 1995. Selective protection against IgG binding to red cells treated with phthalocyanines and red light for virus inactivation. Transfusion, 35:414–20.International Journal of Nanomedicine 2007:2(4) 643
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excited from ground state to 1C60 by photoirradiation. This 
short-lived species is readily converted to long-lived 3C60 via 
intersystem crossing. In presence of molecular oxygen, the 
fullerene can decay from its triplet to ground state, transferring 
its energy to O2, generating singlet oxygen 1O2, known to be 
highly cytotoxic species. In addition, the high-energy species 
1C60 and 3C60 are excellent acceptors and in the presence of a 
donor, can undergo a different process, being easily reduced to 
C60•- by electron transfer. Again, in the presence of oxygen, 
the fullerene radical anion can transfer one electron, producing 
a superoxide anion radical O2•- and hydroxyl radical •OH 
(Yamakoshi et al 2003). The excited fullerene can be reduced 
under biological conditions in the presence of biological 
reducing agents eg, guanosin. On the other hand, singlet 
oxygen and superoxide radical anions are well known reactive 
species towards DNA (Da Ros et al 2001). This property of 
fullerenes renders them potential photosensitizers for their use 
in photodynamic therapy (PDT). Many fullerene conjugates 
with different functional groups possessing biological 
afﬁ  nity to nucleic acids or proteins, are being investigated 
for anticancer activity. In particular, conjugates of C60 and, 
acridine or complementary oligonucleotide, which interact 
with nucleic acids, have been synthesized with the objective 
of increasing cytotoxicity (An et al 1996; Yamakoshi et al 
1996). Cytotoxicity of dendritic C60 monoadduct and malonic 
acid C60 trisadduct was investigated on Jurkat cells, and upon 
exposure to UV light, the cell number was found to drop by 
approximately 19% within two weeks (Rancan et al 2002). 
Ji et al also studied the biodistribution and tumor uptake 
of C60(OH)x in ﬁ  ve kinds of tumor models by radiotracer 
125I-labeled C60(OH)x. (Ji et al 2006).
Iwamoto and Ymakoshi introduced a highly water 
soluble C60- N vinylpyrrolidine copolymer as agent for 
photodynamic therapy (Iwamoto and Yamakoshi 2006). 
C60 was incorporated covalently into poly (vinylpyrrolidone) 
chain via radical polymerization. This nanoparticle was the 
most water-soluble fullerene yet reported and aqueous 
solutions of concentrations even higher than reported 
for saturated C60 in toluene could be generated with this 
method.
Liu et al (2007) demonstrated the use of poly ethylene 
glycol (PEG)-conjugated fullerene containing Gd3+ ions 
for photodynamic therapy in combination with magnetic 
resonance imaging (MRI). The authors demonstrate through 
experimental data that tumor PDT effect was signiﬁ  cantly 
promoted by photosensitizer tumor targetability and MRI 
activity. C60-PEG-Gd was injected into tumor bearing mice. 
The MRI activity was introduced into C60-PEG of PDT 
Figure 4 Closer view of the (HIV PR)-2a complex, showing the H-bond between NH2 or NH3+ groups with Asp 25 and 125. Copyright © 2000. Reproduced with permis-
sion from Marcorin GL, Da Ros T, Castellano S, et al. 2000. Design and synthesis of novel [60]Fullerene derivatives as potential HIV aspartic protease inhibitors. Org Lett, 
2:3955–8.International Journal of Nanomedicine 2007:2(4) 644
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photosensitizer. The chelate incorporation of Gd3+ ions could 
convert C60-PEG derivative to a photosensitizer with both 
the diagnostic and therapeutic functions (Liu et al 2007).
Recently, Mroz et al (2007) investigated the photody-
namic activity of fullerenes derivatized with hydrophilic and 
cationic groups against a range of mouse cancer cell lines. 
They found that, monocationic fullerene is highly effective 
photosensitizer for killing cancer cells by rapid induction of 
apoptosis after illumination.
Antioxidant activity
Results published in 1999 have shown that fullerenes have a 
potential as biological antioxidants. The antioxidant property 
is based on the fact that fullerenes possess large amount of 
conjugated double bonds and low lying lowest unoccupied 
molecular orbital (LUMO) which can easily take up an elec-
tron, making an attack of radical species highly possible. It 
has been reported that up to 34 methyl radicals have been 
added onto a single C60 molecule. This quenching process 
appears to be catalytic. In other words the fullerene can 
react with many superoxides without being consumed. Due 
to this feature fullerenes are considered to be the world’s 
most efﬁ  cient radical scavenger and are described as radical 
sponges (Krusic et al 1991). The major advantage of using 
fullerenes as medical antioxidant is their ability to localize 
within the cell to mitochondria and other cell compartment 
sites, where in diseased states, the production of free radicals 
takes place.
Experiments on rats done by Najla Gharbi and co-
workers proved this remarkable trait. They showed that 
aqueous C60 suspensions prepared without using any polar 
organic solvent, not only have no acute or sub acute toxicity 
in rodents, but also protect their livers against free-radical 
damage (Gharbi et al 2005). Rats are intoxicated with 
CCl4, which led to the formation of trichloromethyl radical 
CCl3 •, causing severe damage to the liver on reaction with 
oxygen. Trichloromethylperoxy radicals CCl3OO•, a highly 
reactive species which rapidly initiates the chain reaction of 
lipid peroxidation (Slater et al 1985), is formed. C60 is able 
to scavenge a large number of these radicals per molecule 
leading to the result that rats pre-treated with C60 and intoxi-
cated with CCl4 showed no liver damage. Considering the 
histopathological examinations and biological tests, pristine 
C60 can be considered as a powerful liver-protective agent 
when used in a dose-dependent manner.
When fullerene is derivatized with polar groups, as in 
case of polyhydroxylated fullerenes (fullerenol) and C60 
tris(malonic)acid, they become water soluble enabling them 
to cross the cell membrane and localize preferentially to 
mitochondria (Foley et al 2002; Youle and Karbowski 2005), 
which generate great masses of cellular oxygen free radicals. 
This phenomenon makes them useful for a variety of medical 
applications (Tsai et al 1997; Lotharius et al 1999; Bisaglia 
et al 2000). These radical scavengers have shown to protect 
cell growth from various toxins that can induce apoptotic 
injuries in vitro (Lin et al 1999; Lin et al 2002; Chen et al 
2004) in different cell types such as neuronal cells (Dugan 
et al 1997; Bisaglia et al 2000), hepatoma cells (Huang et al 
1998), or epithelial cells (Straface et al 1999).
Apoptosis is of critical importance for variety of physi-
ological and pathological phenomenon which led numerous 
scientists to design experiments in this regard. Daniela 
Monti et al investigated the protective activity of this drug 
against oxidative stress-induced apoptosis. 2-deoxy-D-ribose 
(dRib) or TNF-α plus cycloheximide were used as agents 
to trigger apoptosis in human peripheral blood mononuclear 
cells (PBMCs) by interfering with the redox status of cell 
and mitochondrial membrane potential. It was found that 
carboxyfullerenes, also known as C60 tris(malonic)acid, 
was able to protect quiescent PBMCs against apoptosis by 
preserving the mitochondrial membrane potential integrity, 
which is the early stage of apoptosis (Monti et al 2000). Other 
interesting results showing that fullerenes have potential as 
biological antioxidants were also published by Dugan et al 
The authors treated transgenic mice carrying a defective 
copy of the gene encoding for human superoxide dismutase 
(SOD1), which led to amyotrophic lateral sclerosis (ALS), 
with C60 tris(malonic)acid. SOD1 knock out mice treated 
with C60 developed symptoms of disease 10 days later and 
lived 8 days longer than untreated control mice (Dugan et al 
1997).
Fullerenes are also used for cytoprotective action 
against UVA irradiation (Xiao et al 2006). The ultravio-
let A radiation (320–400nm) generates reactive oxygen 
species, which have a biological effect on human skin 
cells, leading to cell damage or cell death. Once again 
the radical scavenging nature of water soluble fuller-
ene derivative namely Radical Sponge® (C60 with 
poly(vinylpyrrolidone)) was utilised to protect human 
ore mammalian cells against oxidative stress, through 
catalytic dismutation of superoxide. The ability of Radical 
Sponge® to enter into depth of human skin epidermis due 
to its stability towards oxidative decomposition makes it 
more reliable than Vitamin C and enables the prevention 
of both UV skin-injuries and skin aging, without photo-
sensitization and cytotoxicity.International Journal of Nanomedicine 2007:2(4) 645
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Water soluble fullerenes namely fullerenols and malonic 
acid derivatives of C60 have attracted great attention in 
the ﬁ  eld of neurosciences. The brain contains a number 
of different unsaturated fatty acids, and underlies aerobic 
metabolism, and has limited ability to regenerate dam-
aged tissues, making it a very sensitive organ towards 
oxidative damage caused by free radicals. These reactive 
oxygen species being O2•- (superoxide), •OH (hydroxyl) 
radicals and closed shell H2O2 molecules (Halliwell 1992). 
Fullerene derivatives have the ability to inhibit the chain 
reaction of lipid peroxidation by scavenging intermediate 
peroxyl radicals, stopping them from attacking adjacent 
fatty acid chains ore membrane proteins, which would lead 
to glutamate-receptor-mediated excitotoxicity and apoptotic 
cell death. In cell culture experiments, C60 tris(malonic)acid 
rescued cortical neurons from a broad range of insults and 
was furthermore found to show robust neuroprotection in a 
number of other cell culture models of neurological disease 
including Parkinson’s disease (Dugan et al 1997).
Fullerenes in drug and gene delivery
The direct delivery of drugs and biomolecules through cell 
membrane into cells has attained increasing attention and 
has put a main focus on the development of efﬁ  cient and safe 
carriers to transport genes or drugs. Transport of any compound 
into the nucleus of an intact cell is a major challenge, as 
transfer is limited by at least three membrane barriers which 
are the cell membrane, the endosomal membrane and the 
nuclear membrane. Hence it is important to fully understand 
the mechanism through which carriers enter cells. There are 
four major groups of drug and gene carriers which are organic 
cationic compounds, viral carriers, recombinant proteins and 
inorganic nanoparticles (Azzam and Domb 2004; Xu et al 
2005). A large number of nanoparticles can be potentially used 
as carriers for the cellular delivery because of their versatile 
properties, including good biocompatibility, selective targeted 
delivery and controlled release of carried drugs. Fullerenes 
belong to the class of inorganic nanoparticles and show wide 
availability due to their small size (~ 1 nm) and biological 
activity. The activities of this allotropic form of carbon rest 
upon the properties of both, the fullerene core and its chemical 
modiﬁ  cation. The fullerene core is very hydrophobic, while the 
functional groups attached to the core add further complexity to 
the behaviour of fullerene molecule. By attaching hydrophilic 
moieties, fullerenes become water-soluble and are capable of 
carrying drugs and genes for the cellular delivery. Derivatized 
fullerene can cross the cell membrane and bind to the 
mitochondria as demonstrated by Foley et al (Foley et al 2002). 
Moreover DNA-functionalized fullerenes are able to enter the 
COS-1 cells and show comparable or even better efﬁ  ciency 
than that of commercially available lipid-based vectors (Isobe 
et al 2001; Nakamura and Isobe 2003). Biochemical studies 
on the mechanism of transfection indicate that the fullerene 
reagent forms a protective sheath around bound DNA, which 
increases the lifetime of DNA in endosomes and thus supports 
their chromosomal incorporation (Isobe et al 2006a). For the 
attachment of DNA-sequences preferably aminofullerenes 
are employed. The detachment of DNA in the cytoplasm can 
be achieved either through loss of its amino groups or loss of 
the binding ability of amines by transformation into neutral 
compounds (Isobe et al 2006b). A lipophilic slow-release drug 
delivery system which employs fullerene derivatives to enhance 
therapeutic efﬁ  cacy in tissue culture was designed by Zakharian 
et al (2005). Modiﬁ  ed fullerenes have the potential to provide 
such a lipophilic slow-release system and is comprised of sig-
niﬁ  cant anticancer activity in cell culture as demonstrated with 
C60-paclitaxel conjugate. Furthermore the ability of fullerenes 
to penetrate through intact skin is widening their application 
in cellular drug and gene delivery (Ryman-Rasmussen et al 
2006). A fullerene-based peptide was synthesized by Rouse 
et al and its ability to penetrate through ﬂ  exed and unﬂ  exed 
skin was observed (Rouse et al 2007). For this study porcine 
skin was used as a model for human skin. It was demonstrated 
that mechanical ﬂ  exion which alters the structural organization 
of skin, increases penetration by compromising the perme-
ability barrier of epidermis. Less is known about the toxicity 
of fullerenes in cell culture and living organism. Some studies 
were carried out on the biological efﬁ  cacy of water-soluble 
fullerenes in vitro (Tsuchiya et al 1995; Dugan et al 1997) 
and in vivo (Yamago et al 1995; Satoh et al 1997) which indi-
cated low toxicity. Another study was designed to determine 
the genotoxicity of fullerenes (a mixture of C60 and C70) in 
bacterial reverse mutation assay including the chromosomal 
aberration test in hamster lung cells followed by the acute oral 
median lethal dose of fullerenes when applied to rats (Mori 
et al 2006). The results revealed that fullerenes did not have 
the ability to induce acute oral toxicity or in vitro genotoxicity. 
Although water-soluble fullerenes are not acutely toxic, they 
are retained in the organism for long periods, raising concerns 
about chronic toxic effects (Yamago et al 1995). However there 
is striking evidence that hydrophilic functional groups on the 
surface of fullerenes dramatically decrease toxicity of raw C60 
molecule (Sayes et al 2004). Underivatized fullerenes aggregate 
in water where they are supposed to cause oxidative damage 
to cellular membranes even at relatively low concentrations 
(20 ppb level).International Journal of Nanomedicine 2007:2(4) 646
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Diagnostic application
The nature of a fullerene cage as a potential “isolation chamber” 
recommends the possibility to carry an unstable atom, for 
instance a metal atom, within the interior of the molecular 
cage forming so-called endofullerenes/metallofullerenes that 
would be able to isolate reactive atoms from their environment. 
Several studies have already shown that fullerene cages are 
relatively non-toxic and resistant to body metabolism (Moussa 
et al 1997; Chen et al 1998). Biodistribution studies with water 
soluble derivatives of C60 demonstrate that these compounds 
are primarily localised in the liver and their clearance is very 
slow (Moussa et al 1997). Metallofullerenes introduce no 
release of the captured metal atom under in vivo conditions, in 
contrast to metal chelates, they have a potential in diagnostic 
application. Endofullerenes can be applied as magnetic reso-
nance imaging contrast agent MRI, X-ray imaging agent and 
radiopharmaceuticals.
Fullerol, which is highly water soluble, was chosen for 
radiolabeling with 67Ga3+. The results show that radiolabeling 
yields could reach 97% under the best applied conditions. The 
radiochemical purity of 67Ga-C60(OH)x solution kept at 37 °C
|remained at 88% after 212 hours. Results from biodis-
tribution studies provide evidence for localization of this 
compound to macrophages, because the fullerene derivative 
localized predominately to bone marrow, liver and spleen 
with slow clearance and negligible amounts in the blood (Li 
et al 2005). The distribution and metabolism of these newly 
designed derivatives were also extensively investigated. It 
was found that holmium metallofullerol molecules could 
signiﬁ  cantly accumulate in liver; moreover, they could be 
detected in the bone. The localization of the metallofullerol 
in bone can bring an important conclusion that these species 
are selectively targeted to tissues rich in macrophages and 
might be useful chemotherapeutic agent for treatment of 
leukemia and bone cancer (Thrash et al 1999).
In addition, evidence was provided for the formation of 
99mTc@C60 and 99mTc@C70, the ﬁ  rst direct encapsulation 
of a radionuclide during fullerene formation. These results 
have already shown the utility of ultra low level radioactivity 
detection methods for the identiﬁ  cation of trace levels of 
endofullerenes. As it has been mentioned, such encapsulation 
of a radionuclide would facilitate their inert transport through 
biological systems. Applying the proper antibody label, the 
radionuclide could be transported to the region of interest 
without considerable interaction between radiolabel and the 
antibody (Karam et al 1997).
For quite long time, bigger fullerenes (C80 or C82) were 
believed to restrict the incorporation of more than two, larger 
lanthanide elements. It has already been reported by Cao et al 
(2002) that a dimetallic species of titanium was incorporated 
into C80 cage. It is worth mentioning that the encapsulation 
of a lanthanide metal inside C82 cage, the metal atom typi-
cally introduces a trivalent oxidation state in order to partially 
ﬁ  ll the lowest unoccupied molecular orbitals (LUMOs) of 
fullerenes, thus creating an open-shell electronic state (Liu 
and Sun, 2000). Only few lanthanide elements among others 
cerium and praseodyum were found to form higher symmetry 
(Ih) C80 cage encapsulates (Ding et al 1996).
Interestingly, Iezzi and his co-workers recently synthe-
sized an endohedral metallofulerene by trimetallic nitride 
template process that allowed the formation of a stable high 
symmetry (Ih) [Lu3N] +6@[C80] cage (Iezzi et al 2002). In 
comparison with Sc3N@C80 metallofullerene yields were 
found to be considerably lower for lutenium metallofulleren 
than for scandium metallofullerene (Stevenson et al 1999). 
Due to the similarities between Sc3N@C80 and Lu3N@C80 
in spectroscopic data and chromatographic behavior, one can 
conclude that the trimetallic nitride cluster has a minimal 
inﬂ  uence on properties of fullerene cage.
In another approach, fullerene derivatives were used as 
a carrier for serum protein proﬁ  ling, which is a powerful 
tool for the identiﬁ  cation of protein signatures for patholo-
gies and biomarker discovery, using material-enhanced 
laser desorption/ionisation (MELDI) technique. MELDI is 
a new form of laser desorption/ionisation and introduced in 
2005 in our laboratory is (Feuerstein et al 2006; Rainer et al 
2006). Three fullerene compounds in particular: dioctadecyl-
methano-[C60]fullerene (DOMF), [C60]fullereneacetic acid 
(FAA) and copper(II) iminodiacetic acid-[C60]fullerene 
(IDAF) were tested for their ability as MELDI carrier materi-
als using human serum (Vallant et al 2006). The fullerene 
materials are incubated with serum and the absorbed proteins 
and peptides are analyzed with MALDI-TOF MS. Each 
of the three fullerenes gave reproducible mass spectra, but 
their spectra were notably different, reﬂ  ecting the different 
components trapped by the diverse adsorption behaviors. 
For screening the proteins in serum, direct laser irradiation 
of the adsorbed proteins was possible over the range m/z 
2000–30,000. However, for identiﬁ  cation and fractionation, 
it was necessary to elute the adsorbed compounds and subject 
them to MALDI-TOF MS analysis. Figure 5 illustrates the 
inﬂ  uence of fullerene derivatizations on the MELDI protein 
proﬁ  le patterns in the m/z range of 2300–6300 (A, B and 
C) and 10200–20000 (D, E and F); (A and D) dioctadecyl 
methano[60]fullerene, (B and E) [C60]fullerenoacetic acid, (C 
and F) Cu(II)-IDA-[C60]fullerene. In the low-molecular-weight International Journal of Nanomedicine 2007:2(4) 647
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region at m/z 1000–4000, where most potential biomarkers are 
expected to be found, FAA gave several peaks in the spectrum, 
whereas DOMF gave none whatsoever. Unfortunately, the 
signal intensities in case of FAA were too low for compound 
identiﬁ  cation by MS/MS analysis, so again, the compounds 
needed to be eluted for identiﬁ  cation.
Conclusion
Since fullerenes were discovered at the end of last century, 
many new ﬁ  ndings and important aspects on these carbon 
molecules have been accumulated to form a new exciting 
scientiﬁ  c ﬁ  eld. Recent developments suggest that many 
of proposed fullerene applications are to be practical 
technologies in a wide range of areas such as IT devices, 
diagnostics, pharmaceuticals, environmental and energy 
industries. The direct application of fullerene and their 
derivatives to biological targets is now yielding promising 
applications in medicine. Such attention to them is caused 
by unique chemical and physical properties of the fullerene 
core, including of their photodynamic properties. The 
hydrophobic spheroid and the radical sponge character of 
fullerene are responsible for the activity in different ﬁ  elds. 
Fullerenes have unusual redox chemistry and may be 
reversibly reduced by up to six electrons. These, along with 
the low toxicity detected so far in fullerenes, are sufﬁ  cient 
to stimulate researchers in chemistry and in biology to unite 
their efforts and systematically investigate the biological 
properties of these fascinating molecules. A wave of research 
and development activities all over the world has led to large 
number of application-oriented patents, spanning a very 
broad range spectrum of potential commercial applications, 
including: anticancer anticancer drug delivery systems using 
photodynamic therapy, HIV drugs, and cosmetics to slow 
down the aging of human skin.
The fullerene ﬁ  eld is going to contribute to industries. In 
the past, high production cost of fullerenes has been the main 
obstacle in the development of fullerene market. We are now 
seeing a very rapid decline in price which will open the door 
to a host of other applications. In addition, many industrial 
applications of fullerenes are now being commercialized.
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